CD276 and cancer: Noticeably, new potential targets including proteins expressed by cancer stem cells (CSC), such as PTK7, ephrin-A4, 5T4 and in the TME, such as CD205, CD25, B7-H3, are under investigation with some of these that already reached clinical phases of drug development [107, 108].